FDA Clarifies Expectations for Completeness Assessments for Drug Master Files
This article was originally published in The Gold Sheet
Executive Summary
FDA has clarified its requirements for DMF completeness acceptance following complaints that the draft guidance was too vague. FDA elaborates on what constitutes a single drug substance, single manufacturing process and starting materials.
You may also be interested in...
Updated US DMF Guidance Reflects GDUFA II, Electronic Submissions
US FDA’s first revision of its foundational Drug Master Files guidance in 30 years contains few surprises but incorporates statutory and regulatory actions. Among the changes: a new section requiring electronic submission of DMFs and a section reflecting GDUFA II completeness assessments in Type II DMFs.
FDA Revises Guidance on DMFs and Prior Approval Supplements to Reflect GDUFA II
FDA has revised references in guidance to generic drug user fee requirements that changed under GDUFA II on Oct. 1. One guidance document no longer says for generics firms to pay user fees for prior approval supplement reviews. Another gives review goals for drug master file completeness assessments.
FDA Revises Guidance on DMFs and Prior Approval Supplements to Reflect GDUFA II
FDA has revised references in guidance to generic drug user fee requirements that changed under GDUFA II on Oct. 1. One guidance document no longer says for generics firms to pay user fees for prior approval supplement reviews. Another gives review goals for drug master file completeness assessments.